Menu
Search
|

Menu

Close
X

Jaguar Health Inc JAGX.OQ (NASDAQ Stock Exchange Capital Market)

1.59 USD
+0.16 (+11.19%)
As of Sep 17
Previous Close 1.43
Open 1.46
Volume 444,263
3m Avg Volume 170,877
Today’s High 1.60
Today’s Low 1.46
52 Week High 175.00
52 Week Low 1.01
Shares Outstanding (mil) 9.38
Market Capitalization (mil) 16.50
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY19
2
FY18
4
FY17
4
FY16
0
EPS (USD)
FY19
-16.832
FY18
-181.693
FY17
-642.578
FY16
-1,438.819
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
3.17
7.90
Price to Book (MRQ)
vs sector
10.66
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
78.56
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-122.38
12.69
Return on Equity (TTM)
vs sector
-249.99
17.13

EXECUTIVE LEADERSHIP

James Bochnowski
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Lisa Conte
President, Chief Executive Officer, Director, Since 2013
Salary: $480,000.00
Bonus: $30,000.00
Karen Wright
Chief Financial Officer, Treasurer, Since 2015
Salary: $280,667.00
Bonus: $30,000.00
Steven King
Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary, Since 2014
Salary: $287,045.00
Bonus: --
Gregory Divis
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

201 Mission St Ste 2375
SAN FRANCISCO   CA   94105-1839

Phone: +1415.8965081

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

SPONSORED STORIES